Phase II Trial of Parathyroid Hormone After Double Umbilical Cord Blood Transplantation
12/2012
Journal Article
Authors:
Ballen, K.;
Mendizabal, A.M.;
Cutler, C.;
Politikos, I.;
Jamieson, K.;
Shpall, E.J.;
Dey, B.R.;
Attar, E.;
McAfee, S.;
Delaney, C.;
McCarthy, P.;
Ball, E.D.;
Kamble, R.;
Avigan, D.;
Maziarz, R.T.;
Ho, V.T.;
Koreth, J.;
Alyea, E.;
Soiffer, R.;
, ;
Boussiotis, V.;
,
Secondary:
Biol Blood Marrow Transplant
Volume:
18
Pagination:
1851-1858
URL:
http://www.ncbi.nlm.nih.gov/pubmed/22766223
Keywords:
Cord blood; Engraftment; Transplantation
Abstract:
Transplantation of 1 or 2 umbilical cord blood products is a useful alternative stem cell source. However, the limited number of stem cells in each infusion results in slow engraftment. In mouse models, administration of parathyroid hormone (PTH) is an effective way to enhance the ability of limited numbers of hematopoietic stem cells to support hematopoiesis. In this study, patients received either a myeloablative or a reduced-intensity double umbilical cord blood transplantation, followed by PTH at 100 μg/day for 28 days. Thirteen patients (median age, 42 years) were enrolled. All patients engrafted; the median time to neutrophil and platelet engraftment of >20 × 10(9) cells/L was 30 days and 61 days, respectively. The incidence of grade II-IV acute GVHD was 38.5% at day 100. Four deaths occurred before day 100, prompting early study closure. No patient who received a myeloablative regimen relapsed. Overall survival at 6 months after transplantation was 62%, and disease-free survival at 2 years was 39%. At the dose and schedule studied, there was no evidence that PTH influenced blood count recovery.
